Ropivacaine: Difference between revisions
m (Protected "Ropivacaine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 55: | Line 55: | ||
[[pt:ropivacaína]] | [[pt:ropivacaína]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 15:46, 20 August 2012
| File:Ropivacaine.png | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Parenteral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 87%–98% (epidural) |
| Metabolism | Hepatic (CYP1A2-mediated) |
| Elimination half-life | 1.6–6 hours (varies with administration route) |
| Excretion | Renal 86% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C17H26N2O |
| Molar mass | 274.4 g/mol |
|
WikiDoc Resources for Ropivacaine |
|
Articles |
|---|
|
Most recent articles on Ropivacaine Most cited articles on Ropivacaine |
|
Media |
|
Powerpoint slides on Ropivacaine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Ropivacaine at Clinical Trials.gov Clinical Trials on Ropivacaine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Ropivacaine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Ropivacaine Discussion groups on Ropivacaine Patient Handouts on Ropivacaine Directions to Hospitals Treating Ropivacaine Risk calculators and risk factors for Ropivacaine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Ropivacaine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ropivacaine (rINN) (Template:PronEng) is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin.
History
Ropivacaine was developed after bupivacaine was noted to be associated with cardiac arrest in 0.5–0.75% of cases, particularly in pregnant women. Ropivacaine was found to have less cardiotoxicity than bupivacaine in animal models.
Clinical use
Indications
Ropivacaine is indicated for local anaesthesia including infiltration, nerve block, epidural and intrathecal anaesthesia in adults and children over 12 years. It is also indicated for peripheral nerve block and caudal epidural in children 1–12 years for surgical pain. It is also sometimes used for infiltration anaesthesia for surgical pain in children.
Ropivacaine is often co-administered with fentanyl for epidural analgesia, for example in pregnant women during labour.
Contraindications
Ropivacaine is contraindicated for IV regional anaesthesia (IVRA).
Adverse effects
Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur.
Systemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression.[1]
Treatment of overdose: "Lipid rescue"
As for bupivacaine, there is evidence that Intralipid, a commonly available intravenous lipid emulsion, can be effective in treating severe cardiotoxicity secondary to local anaesthetic overdose in animal experiments[2] and in humans.[3][4][5]
References
- ↑ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
- ↑ Weinberg, G, Ripper, R, Feinstein, DL, Hoffman W. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med 2003;28:198-202. PMID 12772136
- ↑ Picard J, Meek T. Lipid emulsion to treat overdose of local anaesthetic: the gift of the glob. Anaesthesia 2006;61:107-9. PMID 16430560
- ↑ Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful Use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology 2006;105:217-8. PMID 16810015
- ↑ Litz, RJ, Popp M, Stehr S N, Koch T. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. Anaesthesia 2006;61:800-1.
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Local anesthetics
- Obstetrics